Information  X 
Enter a valid email address

Osirium Technologies (OSI)

  Print   

Wednesday 12 May, 2021

Osirium Technologies

Results of General Meeting

RNS Number : 4427Y
Osirium Technologies PLC
12 May 2021
 

12 May 2021

 

Osirium Technologies plc

 

("Osirium" or the "Company")

 

Results of General Meeting

 

Osirium Technologies plc (AIM: OSI.L) is pleased to announce that at its General Meeting held earlier today, the Resolution as referred to in the Circular to shareholders dated 26 April 2021 incorporating Notice of the General Meeting (the "Circular") was duly passed by shareholders on a poll vote.

 

The results of the poll are set out below:

Resolution

Votes for

% of votes cast for

Votes against

% of votes cast against

Votes cast in total

Total votes cast as a % of issued share capital

Votes withheld

Special resolution to authorise the allotment  of  new Ordinary Shares pursuant to the Placing and Subscription on a non-pre-emptive basis

10,111,032

over 99.99

40

less than 0.01

10,111,072

43.22

2,000

Application has been made for an aggregate of 5,987,259 new Ordinary Shares (being the total of the Second Placing Shares, the Subscription Shares, and a further allotment of 22,728 ordinary shares at the Placing Price) (together the "New Ordinary Shares") to be admitted to trading on AIM. It is anticipated that trading of the New Ordinary Shares will commence at 8 a.m. on 18 May 2021.

Total voting rights

Following admission of the New Ordinary Shares the number of Ordinary Shares of 1 pence in issue and number of voting rights will be 29,382,014. The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Terms used but not defined in this announcement shall have the meanings given to such terms in the Circular, which can be viewed at https://osirium.com/investors/aim-rule-26/ .

For further information, please contact:

 

Osirium Technologies plc


David Guyatt, Chief Executive Officer

+44 (0) 118 324 2444

Rupert Hutton, Chief Financial Officer


Martin Kay, Company Secretary




Stifel (Nomad and Joint Broker)

+44 (0) 207 710 7600

Fred Walsh / Richard Short




Alma (Financial PR)

+44 (0) 203 405 0205

Hilary Buchanan / Josh Royston / Kieren Breheny


 

 

 

About Osirium

 

Osirium Technologies plc (AIM: OSI.L) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Security solutions. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

 

Osirium has defined and delivered what the Directors view as the next generation Privileged Access Management solution. Osirium's award-winning Privileged Task Management module further strengthens Privileged Account Security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers. Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched Privileged Process Automation, providing a highly-flexible platform for automating essential IT processes to set a new benchmark in IT Process Automation. This was followed by the launch of Privileged Endpoint Manager in December 2019, bringing the total portfolio to three complementary solutions.

 

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016. For further information, please visit www.osirium.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMBLGDUUBBDGBD

a d v e r t i s e m e n t